{"nctId":"NCT04249687","briefTitle":"Treatment of Moderate to Severe Lateral Canthal Lines","startDateStruct":{"date":"2020-02-10","type":"ACTUAL"},"conditions":["Lateral Canthal Lines"],"count":303,"armGroups":[{"label":"Treatment","type":"EXPERIMENTAL","interventionNames":["Biological: botulinum toxin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"botulinum toxin","otherNames":["QM1114-DP"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female 18 years of age or older.\n2. Moderate to severe LCL at maximum smile as assessed by the Investigator.\n3. Moderate to severe LCL at maximum smile as assessed by the subject.\n\nExclusion Criteria:\n\n1. Previous use of any Botulinum toxin treatment in facial areas within 9 months prior to study treatment.\n2. Female who is pregnant, breast feeding, or intends to conceive a child during the study.\n3. Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With a â‰¥ 2-grade Improvement From Baseline on the Lateral Canthal Line Investigator and Subject Assessments at Maximum Smile at One Month.","description":"The investigator and subject evaluate the subject's LCL severity using a 4-grade scale (0 = none and 3 = severe)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Achieve Grade 0 or 1 in Lateral Canthal Line Investigator Scale at Maximum Smile.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":230},"commonTop":["Injection site bruising","COVID-19","Sinusitis","Headache","Nasopharyngitis"]}}}